Hyojin Park is an Associate Research Scientist in the Department of Cardiovascular Medicine at Yale School of Medicine. She holds a PhD in Biochemistry from Yonsei University (2014) and a BS in Biochemistry from the same institution (2008). Her research focuses on vascular biology, particularly the mechanisms underlying blood-retina barrier integrity, arteriovenous malformations, and endothelial cell signaling in cardiovascular diseases. Key collaborators include Dr. Anne Eichmann and Dr. William Sessa. Her work spans topics such as angiogenesis regulation, molecular pathways in atherosclerosis, and the role of genetic factors like ALK1 and SMAD4 in vascular disorders. Park’s studies integrate experimental models and molecular techniques to explore vascular development and dysfunction. She has contributed to over 15 peer-reviewed publications since 2011, with recent emphasis on retinal vascularization and flow-migration dynamics in hereditary hemorrhagic telangiectasia. Research interests also include epigenetic regulation (DNA methylation), microRNA effects on endothelial cells, and drug development targeting vascular leakage. Her interdisciplinary approach bridges basic science and translational medicine, aiming to address unmet clinical needs in vascular pathologies.
Yury M. Morozov is a Research Scientist in Neuroscience at the Yale School of Medicine. He specializes in advanced microscopy techniques, including 3D reconstruction of neural structures from electron micrographs, and investigates neurodegenerative diseases and central nervous system pathologies. His work focuses on calcium signaling, mitochondrial dynamics, and tau protein pathology in non-human primate models of Alzheimer’s and cognitive disorders. Education: PhD in Neurobiology, National Phytopathology Research Institute (1991) Stipendiary Research Fellowship, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest (2003) Research Interests: Ultrastructural analysis of neuronal and glial cells Role of calcium pathways in prefrontal cortex dysfunction Mitochondrial abnormalities in aging and neurodegeneration 3D reconstruction techniques for neural architecture Recent Research Trends: Dr. Morozov’s studies highlight the critical role of calbindin and Cav1.2 in prefrontal neurons, linking calcium dysregulation to cognitive decline. His work also demonstrates trans-synaptic tau propagation in Alzheimer’s models and identifies Golgi apparatus dysfunction as a precursor to mitochondrial pathology. Advising & Grants: Collaborates closely with Pasko Rakic, Amy Arnsten, and others on NIH-funded projects exploring neurodegenerative mechanisms. No formal student advisees listed. Labs & Teams: Member of the Rakic Lab, focusing on cortical development, synaptic plasticity, and ultrastructural neurobiology. Active in cross-departmental initiatives at Yale School of Medicine.
Suleyman Coskun is an Associate Research Scientist in the Department of Neurosurgery at Yale University School of Medicine. He holds a PhD in Molecular and Cellular Biology from Baylor College of Medicine and an MSc in Biotechnology from Middle East Technical University. His research focuses on genetic and epigenetic mechanisms underlying brain cancers, including meningiomas and gliomas. He has held a visiting professorship at Middle East Technical University (2022) and received prestigious awards like the TÜBİTAK International Fellowship (2020) and Fulbright Visiting Scholar (2004). His key research areas include tumor genomics, stem cell niche regulation, and vascular biology in neurological diseases. Recent work has identified critical pathways in meningioma development and characterized the role of osteolineage cells in hematopoietic stem cell (HSC) maturation. He collaborates extensively with teams at Yale and globally on projects like genomic analyses of brain tumors and nanoparticle-based gene editing. Dr. Coskun’s lab is located at the Anlyan Center, Yale, and his work spans translational research from molecular mechanisms to potential therapeutic targets. Notable contributions include studies on PPIL4’s role in brain angiogenesis and super-enhancer-driven hedgehog signaling in meningiomas.
Pawel Kiela, DVM, PhD, is a Professor in the Department of Pediatrics at the University of Arizona. His research focuses on the interplay between gastrointestinal disorders, inflammation, and cancer, with a particular emphasis on pediatric populations. His work explores mechanisms linking gut microbiota dysbiosis, immune responses, and disease progression in conditions such as inflammatory bowel disease (IBD), colorectal cancer, and PANDAS. Recent studies highlight the role of ion transporters (e.g., NHE3, NCX3), microbiome dynamics, and targeted therapies in modulating disease outcomes. Key research interests include understanding how genetic variants (e.g., NTHL1) contribute to tumor initiation, investigating the therapeutic potential of miRNA-based therapies and pro-drugs, and analyzing the impact of environmental factors (e.g., diet, antibiotics) on gut health. His studies often utilize mouse models to dissect pathogenic mechanisms and test novel interventions. Dr. Kiela’s publications reflect a multidisciplinary approach, combining molecular biology, immunology, and clinical trials. Notably, his work demonstrates how gut microbiota transplantation can induce colitis in germ-free mice, underscoring the microbiome’s role in disease. He has also explored the role of microglia in neuroinflammatory conditions and the efficacy of stabilized chlorine dioxide in reducing mucositis. No scientific awards are explicitly mentioned in the provided texts. His research is supported by collaborations across pediatrics, immunology, and oncology, though specific grants or funding sources are not detailed here.
Linnea Weiss is an Associate Research Scientist in the Department of Genetics at Yale University’s Yale School of Medicine. Her work focuses on genetics, neuroscience, immunology, and developmental biology, with a particular emphasis on gene regulation, neuronal development, and immune cell function. She holds a PhD from Yale University and contributes to interdisciplinary research spanning molecular mechanisms and cellular biology. Her research interests include the molecular basis of neurodevelopmental disorders, immune cell dynamics, and the genetic underpinnings of sensory systems. Recent studies highlight her exploration of mRNA stability, neutrophil behavior in immune responses, and neuronal connectivity in the cerebral cortex. Her work integrates experimental models like Drosophila to study taste systems and mouse models to investigate hematopoietic processes. Publications from 2011 to 2024 reflect her expertise in genetics, immunology, and developmental biology. Key themes include gene-phenotype relationships in neurodevelopmental disorders, neutrophil-mediated immune regulation, and molecular pathways governing neuronal polarity and connectivity. Linnea Weiss has not been explicitly noted for scientific awards in the provided information. She collaborates within the Genetics department and contributes to Yale’s broader research ecosystem, though specific grants or teams are not detailed here.
Timothy Nottoli, PhD, is a Senior Research Scientist in the Department of Comparative Medicine at Yale University, and Co-Director of the Yale Genome Editing Center (YGEC). He holds a PhD from the University of California, Berkeley (1992) and a BA from the University of California, Santa Barbara (1985). His research focuses on genome editing, mouse models for disease mechanisms, and genetic regulation in developmental and evolutionary contexts. Dr. Nottoli collaborates extensively with investigators like James Noonan and Shuichi Ahsan, advancing studies in gene therapy, cardiovascular malformations, and genetic disorders such as systemic lupus erythematosus and microvillus inclusion disease. His work integrates CRISPR-based tools to engineer precise genetic modifications in mice, enabling disease modeling and therapeutic testing. Key projects include enhancing AsCas12a knock-in efficiency for immunogenetics studies and exploring evolutionary innovations in regulatory elements linked to developmental genes. His lab’s contributions span molecular biology, epigenetics, and translational medicine, with implications for personalized therapies and understanding genetic pathways. Dr. Nottoli’s academic roles include co-directing the YGEC, fostering interdisciplinary genome-editing initiatives. He has authored over 30 peer-reviewed publications, addressing topics like DNA repair mechanisms, hypertension pathophysiology, and genomic instability. His research emphasizes translational applications, such as developing mouse models to study human diseases and testing pharmacological interventions (e.g., isradipine for aldosteronism). Collaborative networks extend to departments like Neurosurgery and Genetics, reflecting his commitment to team science. Professional activities include advising on genomic tools and mentoring researchers in gene-editing techniques. His lab, part of the Yale School of Medicine, is located at the Anlyan Center. Contact details include an academic office phone (203.737.4325) and email for collaborations. No formal awards are listed, though his impactful contributions to genome editing are recognized through his publications and institutional roles.
Herbert Levine is a University Distinguished Professor of Physics at Northeastern University's College of Engineering, with a joint appointment in Bioengineering. His research focuses on Biological Physics, Non-linear Dynamics, and Statistical Physics applied to cancer biology, immunology, and cellular systems. Key research areas include modeling cancer progression/metastasis, tumor-immune system interactions, metabolic plasticity, and the mechanics of collective cell motility. He co-directs the NSF Physics Frontier Center for Theoretical Biological Physics, emphasizing interdisciplinary approaches. His work combines mathematical modeling with experimental data to explore gene regulatory networks influencing cell fate decisions, EMT plasticity, and drug resistance mechanisms. Major contributions include frameworks linking metabolic states to cancer persistence and analyzing immune evasion strategies in tumors. Grants: NSF Physics Frontier Center (Northeastern expansion), DMS/NIGMS funding for EMT stemness research Labs/Teams: Center for Theoretical Biological Physics, interdisciplinary cancer modeling group
Daniel G. Anderson is a Professor in the Department of Chemical Engineering and the Institute for Medical Engineering and Science at the Massachusetts Institute of Technology. He holds additional appointments as a Member of the Marble Center for Cancer Nanomedicine, Associate Member of the Broad Institute of MIT and Harvard, and Associate Member of the Ragon Institute at MGH, MIT and Harvard. His research spans multiple institutions including the Koch Institute for Integrative Cancer Research and the Harvard-MIT Division of Health Science and Technology. Anderson received his BA in mathematics and biology from the University of California at Santa Cruz and his PhD in molecular genetics from the University of California at Davis. His educational background laid the foundation for his interdisciplinary approach to biomedical engineering and nanotechnology. Professor Anderson's research focuses on the intersection of biology and engineering to develop novel medical devices and therapies. His laboratory pioneers the development of smart materials, nanoparticles for drug delivery, living medical devices, and next-generation nanotherapeutics. Key research areas include creating synthetic nanoparticles that act as artificial viruses for genetic therapy delivery, developing biomaterials for tissue engineering, and engineering responsive drug delivery systems that can integrate with the body for customized treatment. His work spans applications in cancer, diabetes, and other chronic diseases. Analysis of Anderson's recent publications reveals a strong trend toward RNA therapeutics, particularly in the development of lipid nanoparticles for mRNA delivery. His research increasingly incorporates AI-guided design approaches and focuses on targeted delivery to specific organs like the lungs. There's also a clear progression toward clinical applications, with several technologies moving from basic research to clinical development. 2023 Wilhelm Exner Medal for contributions to nanotherapeutics and biomaterials Elected to the National Academy of Inventors for inventions with tangible societal impact Elected to the National Academy of Medicine for outstanding contributions to medical research Professor Anderson has advised numerous graduate students, postdocs, and researchers, many of whom have received funding through the Gordon Tang Goodwin Student Support Fund to attend major scientific conferences. His lab has secured significant funding, including a $25 million grant from Sanofi to develop next-generation delivery technology for mRNA vaccines and therapeutics. Anderson's research has resulted in over 500 publications, patents, and patent applications, and has led to the founding of multiple biotechnology companies including Living Proof, Olivo Labs, CRISPR Therapeutics, Sigilon Therapeutics, Verseau Therapeutics, Orna Therapeutics, and VasoRx. His laboratory continues to push the boundaries of what's possible in medical device engineering and therapeutic delivery.
Alexander R. Gerson is an Associate Professor in the Department of Biology at the University of Massachusetts Amherst. His research focuses on integrative eco-physiology, particularly the environmental physiology of birds, emphasizing how they adapt to extreme conditions like long-distance migration and desert heat. He holds a Ph.D. from the University of Western Ontario and has expertise in avian thermoregulation, protein catabolism during flight, and stopover ecology. Educations: B.S., SUNY College of Environmental Science & Forestry, 2004 M.S., University of Western Ontario, 2007 Ph.D., University of Western Ontario, 2012 His research spans multiple levels of biological organization, from cellular mechanisms to community-level responses. Key projects include investigating flight energetics, organ catabolism under dehydration, and heat tolerance strategies in desert birds. He has been funded by grants such as the NSERC Discovery Grant and has contributed to high-impact studies, including the 2011 Science paper on protein catabolism in migratory birds. His work has been covered by media like National Public Radio and Los Angeles Times , highlighting discoveries about birds' physiological adaptations to extreme environments.
Dr. Jesse Rinehart is an Associate Professor in the Department of Cellular & Molecular Physiology at Yale School of Medicine, with a joint appointment in the Systems Biology Institute. His research focuses on decoding protein phosphorylation mechanisms using innovative phosphoproteomics and synthetic biology approaches. He developed a groundbreaking E. coli-based technology enabling site-specific phosphoserine incorporation into human proteins, advancing studies of phosphorylation networks. Education: PhD in Molecular Biophysics and Biochemistry, Yale University School of Medicine (2004) MS, Yale University (1999) BA, Kalamazoo College (1998) Research Interests: Dr. Rinehart’s work integrates systems biology with molecular physiology, emphasizing phosphorylation’s role in disease mechanisms such as cancer and hypertension. His lab explores how phosphorylation regulates ion transporters, signaling pathways, and metabolic processes. Recent breakthroughs include engineering genomically recoded organisms and identifying therapeutic targets for glioblastoma and kidney diseases. Key Contributions: Structural studies of sodium-chloride cotransporters and their inhibition by diuretics Development of phosphoserine resource tools for proteome-wide analysis Identification of PKM2’s role in gene regulation via G-quadruplex interactions Collaborations with neuro-oncology and diabetes research groups Labs & Teams: The Rinehart Lab at Yale West Campus employs interdisciplinary approaches, combining biochemistry, genetics, and computational modeling. Collaborations extend across departments including Biophysics, Pharmacology, and the Cancer Center.
Leonid Tyan is an Associate Research Scientist in the Department of Cellular & Molecular Physiology at Yale School of Medicine. He holds a PhD from Eberhard Karls Universität Tübingen (2012). His research focuses on ion channel biology, cellular physiology, and mechanisms underlying cardiac arrhythmias, particularly atrial fibrillation. He investigates the role of caveolae, membrane potential regulation, and calcium signaling in cardiac and cellular contexts. Collaborations include work with David Zenisek, Michael Caplan, and Mustafa Khokha. His studies span from molecular mechanisms to computational modeling of cardiac cells, contributing to understanding arrhythmogenesis and developmental processes. Research Interests: Cardiac electrophysiology, ion channel modulation, caveolar microdomains, membrane potential dynamics, and calcium signaling in disease contexts. Key Projects: Mechanisms of atrial fibrillation, caveolin-3's role in ion channel regulation, and mathematical modeling of atrial myocytes. Publications highlight contributions to understanding caveolar-mediated arrhythmias, calcium-dependent processes in pluripotency, and genetic influences on cardiac rhythm. His work bridges experimental and computational approaches to elucidate disease mechanisms.
Wenwen Tang, PhD is a Research Scientist in the Department of Pharmacology at Yale School of Medicine. She earned her PhD from Fudan University in 2007 and has since focused on elucidating mechanisms underlying inflammation, neutrophil biology, and acute lung injury. Her work integrates molecular biology, genomics, and immunology to study cellular communication pathways and therapeutic targets for vascular and immune-related disorders. Research Interests: Dr. Tang’s research explores the roles of Wnt signaling, extracellular RNA, and lipid transport proteins in regulating neutrophil function, myelopoiesis, and vascular integrity. She investigates mechanisms of acute lung injury, ischemia-reperfusion injury, and inflammatory responses in colitis and other diseases. Her studies often involve single-cell RNA sequencing, mouse models, and collaborative interdisciplinary approaches. Publications: Recent work highlights discoveries in VEGF-D’s role in lung vascular repair, LDLR5-mediated fatty acid transport, and Wnt5-driven myeloid cell reprogramming. These studies contribute to understanding pathological processes and potential therapeutic strategies involving cell surface RNAs and E3 ligase complexes. Lab/Teams: Collaborates closely with departments including Cell Biology, Immunobiology, and Pulmonary Medicine at Yale. Key collaborators include Dianqing Wu, Jun Lu, and Hongyue Zhou.
Professor Martin Clift is a leading academic at Swansea University Medical School, affiliated with the Faculty of Medicine, Health and Life Science and the Department of Biomedical Sciences. He obtained his PhD in Nanoparticle In Vitro Toxicology from Edinburgh Napier University in 2009, followed by postdoctoral research at the University of Bern and the Adolphe Merkle Institute, University of Fribourg (2008–2015). Since 2015, he has been at Swansea University, where he focuses on nanoparticle-cell interactions, nanotoxicology, and advanced in vitro systems to assess health risks posed by engineered materials. His work emphasizes creating biologically relevant models to replace animal testing and investigate nanoparticle effects on human health. His research spans nanotoxicology, particle and fiber toxicology, and alternative in vitro models. He actively contributes to teaching on the MSc Nanomedicine and undergraduate programs in Genetics-Biochemistry and Applied Medical Sciences. Collaborations include international projects on bioaerosol exposure and nanomaterial safety. His >100 publications highlight expertise in in vitro systems, genotoxicity, and lung barrier models. Key projects include developing triple-cell culture models for alveolar barriers, studying indoor air pollution impacts, and investigating carbon nanotube toxicity. He supervises postgraduate students and is available for research supervision. His lab explores disease-based models and nanoparticle effects on immune systems, advancing toxinology and nanomedicine.
Professor Shareen Doak is Professor of Genotoxicology and Cancer at Swansea University Medical School within the Faculty of Medicine, Health and Life Science. She serves as co-lead of the In Vitro Toxicology Group and holds prestigious positions including Editor-in-Chief for Mutagenesis. Professor Doak coordinates the €13Million H2020 PATROLS project and directs the €12Million Celtic Advanced Life Science Innovation Network (CALIN), an Ireland-Wales INTERREG initiative focused on building innovation bridges in life sciences. Her research program focuses on the genotoxic profiles of engineered nanomaterials, mechanisms of DNA damage, and development of advanced 3D culture models for safety assessment to reduce animal testing. In prostate cancer research, she investigates molecular mechanisms of disease progression to identify prognostic biomarker panels for improved clinical management. Her work spans genetic toxicology, nanotoxicology, DNA damage mechanisms, and molecular biology of prostate cancer, with significant implications for nanomaterial safety assessment and cancer diagnostics. Professor Doak's recent publications demonstrate her leadership in adapting OECD test guidelines for nanomaterials, developing advanced in vitro models, and investigating nanomaterial genotoxicity using innovative approaches. Her research shows consistent focus on improving safety assessment methodologies while addressing critical gaps in understanding nanomaterial-biological interactions. She has received notable recognition including being an invited Fellow of the Royal Society of Biology (FRSB) and an elected Fellow of the Learned Society of Wales (FLSW). She serves on the UK Government Committee on Mutagenicity (COM) and is a UK and EUROTOX Registered Toxicologist. Professor Doak's leadership in major international projects and collaborations continues to advance scientific understanding in nanotoxicology and cancer research, with practical applications in healthcare and environmental safety.
Professor Amy Yee is a full Professor in the Department of Developmental, Molecular and Chemical Biology at Tufts University School of Medicine , Boston, Massachusetts. She additionally holds professorial appointments at the Friedman School of Nutrition Science and Policy and is a member of several Graduate Biomedical Sciences programs, including Genetics, Pharmacology, and Cell, Molecular & Developmental Biology. Dr. Yee is the founder and CEO of Cha Therapeutics , a pre-seed women-owned biotech start-up. Education Ph.D. – University of California, Davis, United States A.B. – University of California, Berkeley, United States Postdoctoral Fellowship – Rockefeller University, Molecular Cell Biology (with Dr. Joseph Nevins) Research Focus Dr. Yee’s laboratory integrates basic science discovery with translational medicine to address two major disease areas: breast cancer and genetic epilepsies . Central to her work is the HBP1 transcriptional repressor , a novel tumor-suppressor gene that modulates Wnt signaling , epigenetic reprogramming , and immune-microenvironment interactions . Her group has pioneered studies showing how HBP1 mutations drive invasive breast cancer and how therapeutic targeting of the Wnt pathway can convert “cold” tumors into “hot” ones susceptible to immune checkpoint inhibitors. In parallel, she has uncovered an unexpected role for Wnt-driven Warburg-like metabolism in epileptogenesis, with her mouse models providing the first genetic evidence linking HBP1 loss to spontaneous seizures. Scientific Awards & Honors 25 Year Faculty Service Award – Tufts University (2015) Citation of Appreciation for Review Service – Peking University (2015) Memberships: American Association for Cancer Research, American Epilepsy Society, New York Academy of Sciences, American Society for Biochemistry and Molecular Biology Funding & Grants Dr. Yee has continuously secured competitive extramural funding, including awards from: U.S. Department of Defense (Breast Cancer Research Program & Epilepsy Research) Susan G. Komen Breast Cancer Foundation CURE: Citizens United for Research in Epilepsy (multiple cycles) National Cancer Institute American Institute for Cancer Research Cam Neely Foundation Teaching & Mentorship She is the long-time director of the graduate course Biochemistry of Gene Expression and Signal Transduction , co-director of the MBS biochemistry course, and has formally advised over 50 students toward successful matriculation into medical school and completion of advanced degrees. Laboratory & Enterprise The Yee laboratory at Tufts fosters a collaborative environment across cancer biology, neurogenetics, and drug discovery. Complementing her academic program, Cha Therapeutics is translating her discoveries into first-in-class therapeutics that cross the blood–brain barrier and reprogram tumor immunity, aiming for early-phase clinical trials in triple-negative breast cancer patients.
